Investor Presentation

October 29, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Investor Presentation PursuanttoRegulation30oftheSEBI(ListingObligationsandDisclosureRequirements)Regulations, 2015, we are enclosing herewith the Investor Presentation for Q2 FY26-27. You are requested to take the same on record. Thanking You. Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing, Office No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai – 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Investor Presentation Q2 FY27 Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Alivus Life Sciences Ltd. Financial Performance Review Q2 FY27 | Highlights “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non- GPL business momentum was maintained, while CDMO business saw a meaningful pick-up Dr. Yasir Rawjee during the quarter. Managing Director & The improving business mix and greater operating efficiencies also translated into better Chief Executive Officer underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.” • Revenue from non-GPL business grew by 20.8% YoY. The strong growth momentum was REVENUE 6,820 seen across Europe, Japan, North America, LATAM and ROW markets, reflecting robust global 6.5% 16.0% (IN ₹ MILLION) QoQ YoY demand. Non-GPL business now contributes 79% of our overall revenues. • Gross Margin at 64.4%, was up 420 bps QoQ and 670 bps YoY, on the back of a favourable product mix. EBITDA 2,851 21.8% 47.0% QoQ YoY • EBITDA Margin at 41.8%, was up 520 bps QoQ & 880 bps YoY, due to a combination of (IN ₹ MILLION) better operational efficiencies & product mix. • PAT Margin at 28.9%, was up 390 bps QoQ & 680 bps YoY. PAT 1,968 22.9% 51.3% • The company generated strong free cash flow of ₹2,702 Mn, leading to Cash and Cash (IN ₹ MILLION) QoQ YoY Equivalents (including short term investments) of ₹10,116 Mn as of 30th September 2026. GPL: Glenmark Pharmaceuticals Ltd. Q2 & H1 FY27 Performance Revenue EBITDA PAT EPS (In ₹ Million) (In ₹ Million) 41.8% (In ₹ Million) 28.9% (In ₹) 36.6% 36.4% 6 25.0% 1 88,5 927,6 198, 404,6 028,6 33 9,1.0% 254,2 34 373,2.4% 143,2 158,2 22. 03,11% 22. 305,13% 23 726,1.6% 106,1 869, 6.01 52.21 32.31 40.31 20.61 0 3 1 0 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 39.3% 27.0% 2 1 31.5% 6 898,11 422, 291,5 21 5,2.1% 965,3 15.02 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 5 P&L Highlights | Q2 & H1 FY27 Particulars (In ₹ Million) Q2FY27 Q1FY27 QoQ Q2FY26 YoY H1FY27 H1FY26 YoY FY26 Revenue from Operations 6,820 6,404 6.5% 5,880 16.0% 13,224 11,898 11.1% 25,518 Gross Profit 4,391 3,854 13.9% 3,391 29.5% 8,245 6,706 22.9% 14,853 Gross Profit (%) 64.4% 60.2% +420 bps 57.7% +670 bps 62.3% 56.4% +590 bps 58.2% Other Income 199 224 -11.2% 147 35.4% 423 237 78.5% 604 Employee Benefits Expense 696 683 1.9% 664 4.8% 1,379 1,280 7.7% 2,725 Other Expenses 1,043 1,054 -1.0% 935 11.6% 2,097 1,911 9.7% 4,155 EBITDA 2,851 2,341 21.8% 1,939 47.0% 5,192 3,752 38.4% 8,577 EBITDA Margin (%) 41.8% 36.6% +520 bps 33.0% +880 bps 39.3% 31.5% +780 bps 33.6% Depreciation and Amortisation 218 206 5.8% 184 18.5% 424 355 19.4% 753 Finance Costs 13 13 - 13 - 26 25 4.0% 53 PBT (before exceptional items) 2,620 2,122 23.5% 1,742 50.4% 4,742 3,372 40.6% 7,771 Exceptional items* - - - - - - - - 257 PBT (after exceptional items) 2,620 2,122 23.5% 1,742 50.4% 4,742 3,372 40.6% 7,514 PBT Margin (%) 38.4% 33.1% +530 bps 29.6% +880 bps 35.9% 28.3% +760 bps 29.4% PAT 1,968 1,601 22.9% 1,301 51.3% 3,569 2,516 41.9% 5,645 Net Margin (%) 28.9% 25.0% +390 bps 22.1% +680 bps 27.0% 21.1% +590 bps 22.1% *Impact of new Labour Code Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 34% 34% 27% 2.5 FY23 FY24 FY25 FY26 H1FY27 FY23 FY24 FY25 FY26 H1FY27 • ROICE expanded to ~34% – underscoring strong asset productivity and disciplined capital allocation. • FATR is 2.1 times – Asset turns remained above 2x despite the impact of the ongoing capex cycle. • Strong Balance Sheet – Strong free cash generation of ₹ 2,702 Mn leading to Cash and Cash Equivalents (including short term investments) of ₹ 10,116 Mn as of September 30, 2026. Business Performance Review Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenue In ₹ Million) (Revenue In ₹ Million) 6,343 500 6,070 6,063 5,921 5,464 378 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 • Generic API revenues in Q2FY27 saw a strong • CDMO business saw a growth of 32.3% on QoQ growth of 11.0% YoY. and 79.9% YoY in Q2FY27, on account of strong • Stable growth momentum continued across key traction in existing CDMO projects, supported by 92% markets, including Europe, North America, Japan, 8% recent launches. LATAM, and ROW, driven by new product • Several projects are in advanced stage of launches and healthy demand in the existing discussions. portfolio. Segmental Performance | GPL vs Non-GPL GPL Non-GPL % of Total Revenue % of Total Revenue (In ₹ Million) (In ₹ Million) 35.4% 88.7% 30.0% 75.6% 78.7% 5,681 2,439 70.0% 64.6% 24.4% 21.3% 5,369 2,018 4,711 4,443 4,452 1,437 11.3% 1,451 [Showing first 8,000 characters — download PDF for full document]